Clinical utility of tumor/normal matched sequencing

Hear from Calvin Chao, MD, SVP of Medical Affairs at Tempus as he shares the benefits of a tumor/normal matched sequencing approach, leveraging the Tempus xT test.

Vega DM, Yee LM, McShane LM, et al. Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project. Annals of Oncology. Published online October 2021. doi: https://doi.org/10.1016/j.annonc.2021.09.016

Liu YL, Stadler ZK. The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer? Journal of the National Comprehensive Cancer Network. 2021;19(7):871-878. doi: https://doi.org/10.6004/jnccn.2021.7044

Mandelker D, Ceyhan-Birsoy O. Evolving Significance of Tumor-Normal Sequencing in Cancer Care. Trends in Cancer. 2020;6(1):31-39. doi: https://doi.org/10.1016/j.trecan.2019.11.006

Schoenfeld AJ, Chan JM, Kubota D, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in egfr-mutant lung cancer. Clinical Cancer Research. 2020;26(11):2654-2663. Beaubier N, Bontrager M, Huether R, et al. Integrated genomic profiling expands clinical options for patients with cancer. Nature Biotechnology. 2019;37(11):1351-1360. doi:10.1038/s41587-019-0259-z